SEP 22, 2020
Science
Machavert Pharmaceuticals RAL GTPase Inhibitors Suppress KRAS Cancer Metastasis in Preclinical Animal Model
Machavert hits its preclinical proof of principle milestone that small molecule RAL GTPase…
FEB 20, 2020
Science
The Scientific Advisory Board meeting pinpoints R&D strategy of Machavert
We held the Science Advisory Board (SAB) meeting to review our R&D progress and direction…
FEB 19, 2020
People
CEOCFO Magazine interview with Machavert Pharmaceuticals CEO about taking down the KRAS cancer
The interview focused on core technology currently developed at Machavert and its possible…
AUG 27, 2019
Business
Machavert Pharmaceuticals Signs Exclusive License Agreement to Control RAL GTPase Inhibitors against KRAS Cancers
Machavert obtains worldwide exclusive license to small molecule RAL GTPase inhibitors to treat…
MAR 28, 2019
Science
Machavert Pharmaceuticals Will Present at the Annual Meeting of the American Association of Cancer Research (AACR)
A poster presentation reporting Natural Killer cell activation against cancer by a phospholipid…
FEB 13, 2019
People
CEOCFO magazine interview with Machavert Pharmaceuticals CEO, Dr. Jakub Staszak-Jirkovsky
The interview focused on core technologies currently developed at Machavert and their possible…
JAN 9, 2019
Business
Machavert Pharmaceuticals to Present at Biotech Showcase™, 2019 in San Francisco
Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on immuno-oncology…
NOV 26, 2018
Science
Machavert Pharmaceuticals Unveils a New Bioactive Lipid Drug Candidate for Cancer Treatment
A poster presentation reporting anti-proliferation activity for MP1000 in human KRAS mutant…
NOV 19, 2018
Business
Colorado Advanced Industries Awards Machavert $250K to Develop a Novel Therapeutics Against KRAS Cancers
Grant award to advance RAL GTPase inhibitors in KRAS mutant solid tumors models with Machavert’s…